Oprah Winfreydoesn't do anything small. Not her talk show. Not her book club. And certainly not her weight loss.
The 72-year-old billionaire sat front row at both the Stella McCartney and Chloé shows on 4 and 5 March during Paris Fashion Week, her slimmed-down frame impossible to ignore. She's lost more than 50 pounds over the past two and a half years using GLP-1 medications, the same class of drugs that includesOzempicand Wegovy. The photos went viral within hours.
But here's what makes her Paris appearance more than just another celebrity fashion moment: Winfrey walked away from WeightWatchers in 2024. And the company she once championed as a 'lifestyle' approach to weight management is now fighting for survival.
Winfrey joined the WeightWatchers board in 2015. She invested $43.2 million (£32.3 million) and let the company use her name and face in its marketing. The stock soared.
Then came February 2024. Winfrey announced she wouldn't stand for re-election to the board. According to ABC, WeightWatchers shares dropped 25% in premarket trading the next day, hitting their lowest point since 2001.
She also donated her entire stake in the company to the National Museum of African American History and Culture. WeightWatchers said the move was partly 'to eliminate any perceived conflict of interest around her taking weight loss medications.'
According to reports, Winfrey wore the designer's Elsa pumps in black at the Stella McCartney show, held at the Le Grand Manege Jean Caucanas equestrian centre. Price tag: $990 (£741), WWD reported. Her best friend, Gayle King, seated beside her, wore the same style in brown crocodile-effect.
The next day at Chloé, they matched again—in snake-effect Cleia pumps.
Celebrities wear expensive shoes. That's no news. But it's worth noting who can actually afford the drugs that brought Winfrey here. GLP-1 medications cost between $1,000 and $1,500 (£748 to £1,122) monthly without insurance in the US. In the UK, Wegovy is technically available on the NHS, but strict eligibility rules and shortages push most patients toward private prescriptions.
The math is simple: if you can't afford the treatment, you can't get the results.
Source: International Business Times UK
